Consumer Willingness to Pay for Dengue Vaccine (CYD-TDV, Dengvaxia(®)) in Brazil; Implications for Future Pricing Considerations

Introduction and Objective: Dengue virus is a serious global health problem with an estimated 3.97 billion people at risk for infection worldwide. In December 2015, the first vaccine (CYD-TDV) for dengue prevention was approved in Brazil, developed by Sanofi Pasteur. However, given that the vaccine...

Descripción completa

Detalles Bibliográficos
Autores principales: Godói, Isabella P., Santos, André S., Reis, Edna A., Lemos, Livia L. P., Brandão, Cristina M. R., Alvares, Juliana, Acurcio, Francisco A., Godman, Brian, Guerra Júnior, Augusto A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288336/
https://www.ncbi.nlm.nih.gov/pubmed/28210223
http://dx.doi.org/10.3389/fphar.2017.00041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288336/
https://www.ncbi.nlm.nih.gov/pubmed/28210223
http://dx.doi.org/10.3389/fphar.2017.00041

Ejemplares similares